基于临床-血清学-病理学分类的免疫介导坏死性肌病具有独特表型和预后
该研究纳入138例符合2018年欧洲神经肌肉中心标准的免疫介导坏死性肌病(IMNM)患者,其中抗SRP抗体阳性62例、抗HMGCR抗体阳性32例、肌炎特异性抗体阴性44例,通过临床、血清学和病理学参数聚类分析分为3个聚类并随访缓解与复发。聚类1(n=35)肌酸激酶最高、病程最短、肌无力严重且肌肉活检炎症浸润较多;聚类2(n=79)肌酸激酶最低、炎症浸润中等;聚类3(n=24)起病年龄最轻、病程最长、炎症浸润最少,且达到缓解时间最长、无复发时间较短。发病年龄>55岁、肌纤维再生较多、CD4+ T细胞浸润较多及膜攻击复合物沉积的患者达到缓解的时间预后更有利。
要点
- 聚类分析将IMNM分为3个聚类,各聚类在肌酸激酶水平、病程、肌无力和病理炎症浸润上表现不同。
- 聚类3患者达到缓解时间最长、无复发时间较聚类1和2短。
- 发病年龄>55岁、肌纤维再生较多、CD4+ T浸润较多及膜攻击复合物沉积与更有利的达到缓解时间相关。
核心结论
- 结合临床、血清学和病理学特征的分层可区分IMNM的表型和预后。
- 病理学特征可能影响IMNM患者的长期预后。
研究设计与样本
- 研究纳入138例符合2018年欧洲神经肌肉中心IMNM标准的患者,包括抗SRP抗体阳性62例、抗HMGCR抗体阳性32例和肌炎特异性抗体阴性44例。
- 所有患者均随访并评估缓解和复发。
- 采用基于临床、血清学和病理学参数的聚类分析定义亚组。
主要发现
- 聚类1患者(n=35)肌酸激酶水平最高、病程最短、肌无力严重且肌肉活检炎症浸润较多。
- 聚类2患者(n=79)肌酸激酶水平最低、炎症浸润中等。
- 聚类3患者(n=24)起病年龄最轻、病程最长且炎症浸润频率最低。
- 聚类3患者达到缓解时间最长,中位生存时间61(18.3,103.7)个月 vs 聚类1的20.5(16.2,24.9)个月和聚类2的27(19.6,34.3)个月。
- 聚类3患者无复发时间较聚类1和2短,中位缓解时间95% CI 34(19.9,48.0)个月 vs 73(49.0,68.7)个月和73(48.4,97.6)个月。
关键数值与推荐
- IMNM诊断采用2018年欧洲神经肌肉中心标准。
- 聚类分析基于临床、血清学和病理学参数,将患者分为3个聚类。
- 达到缓解时间的中位生存时间:聚类3为61(18.3,103.7)个月,聚类1为20.5(16.2,24.9)个月,聚类2为27(19.6,34.3)个月。
- 无复发时间的中位缓解时间95% CI:聚类3为34(19.9,48.0)个月,聚类1为73(49.0,68.7)个月,聚类2为73(48.4,97.6)个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of the study was to investigate the characteristics and prognosis of patients with immune-mediated necrotizing myopathy (IMNM) based on clinical, serological and pathological classification. METHODS: A total of 138 patients with IMNM who met the 2018 European Neuromuscular Center criteria for IMNM including 62 anti-SRP, 32 anti-HMGCR-positive and 44 myositis-specific antibody-negative were involved in the study. All patients were followed up and evaluated remission and relapse. Clustering analysis based on clinical, serological and pathological parameters was used to define subgroups. RESULTS: Clustering analysis classified IMNM into three clusters. Cluster 1 patients (n = 35) had the highest creatine kinase (CK) levels, the shortest disease course, severe muscle weakness and more inflammation infiltration in muscle biopsy. Cluster 2 patients (n = 79) had the lowest CK level and moderate inflammation infiltrate. Cluster 3 patients (n = 24) had the youngest age of onset, the longest disease course and the least frequency of inflammatory infiltration. Patients in cluster 3 had the longest time-to-remission [median survival time: 61 (18.3, 103.7) vs 20.5 (16.2, 24.9) and 27 (19.6, 34.3) months] and shorter relapse-free time than those in cluster 1 and 2 [median remission time 95% CI 34 (19.9, 48.0) vs 73 (49.0, 68.7) and 73 (48.4, 97.6) months]. Patients with age of onset >55 years, more regeneration of muscle fibres, more CD4+ T infiltration and membrane attack complex deposition had more favourable outcomes regarding time to achieving remission. CONCLUSIONS: Stratification combining clinical, serological and pathological features could distinguish phenotypes and prognosis of IMNM. The pathological characteristics may impact the long-term prognosis of patients with IMNM.
引用
- Yang H, Zhang L, Tian X, et al. Distinct phenotype and prognosis of immune-mediated necrotizing myopathy based on clinical-serological-pathological classification. Rheumatology (Oxford). 2025. PMID: 39029922. doi:10.1093/rheumatology/keae361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。